Frontiers in Cell and Developmental Biology (2021-04-01)

LECT 2 Antagonizes FOXM1 Signaling via Inhibiting MET to Retard PDAC Progression

  • Xin Li,
  • Pingping Lin,
  • Ye Tao,
  • Xin Jiang,
  • Ting Li,
  • Yunshan Wang,
  • Chenjing Wang,
  • Yu Cao

DOI
https://doi.org/10.3389/fcell.2021.661122
Journal volume & issue
Vol. 9

Abstract

Read online

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with minimally effective treatments, highlighting the importance of developing novel biomarkers and therapeutic targets. Here, we disclosed the mechanisms that leukocyte cell-derived chemotaxin-2 (LECT2) modulates PDAC development using in vitro and in vivo models. LECT2 is downregulated in metastatic PDACs compared with the primary tumor, and its expression is correlated with multiple clinical pathologic features and prognosis. The absence promotes multiple malignant behaviors, including cell proliferation, epithelial-mesenchymal transition, migration, and invasion. In vivo studies showed that LECT2 overexpression inhibits tumor growth and lung metastasis. Mechanistically, LECT2 inhibits FOXM1 signaling by targeting HGF/MET to retard PDAC progression, revealing LECT2 as a promising biomarker and therapeutic target for PDAC in the future.

Keywords